TriangleBiospecimen Collection (NCT04858334)
Biospecimen Collection trial for Pancreatic Acinar Cell Carcinoma (NCT04858334). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with resected pancreatic cancer and a pathogenic or likely pathogenic BRCA1, BRCA2 or PALB2 mutation, after at least 12 weeks of perioperative chemotherapy. No recurrent or metastatic disease is allowed.
The idea: olaparib blocks PARP-mediated DNA repair. Patients receive oral olaparib or placebo twice daily for twelve 28-day cycles. Researchers test whether it delays recurrence.
This phase 2 study plans 152 patients. Kim Reiss Binder leads the NCI-sponsored APOLLO study, with 259 recruiting US sites. Prior progression on platinum excludes participation.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.